ARMC
GILD icon

American Research & Management Company’s Gilead Sciences GILD Stock Holding History

American Research & Management Company’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$2.18M Sell
35,315
-1,677
-5% -$106K 0.6% 50
2022
Q2 		$2.29M Sell
36,992
-961
-3% -$59.5K 0.59% 52
2022
Q1 		$2.26M Sell
37,953
-4,389
-10% -$281K 0.5% 55
2021
Q4 		$3.07M Sell
42,342
-699
-2% -$48.1K 0.67% 45
2021
Q3 		$3.01M Sell
43,041
-2,799
-6% -$197K 0.69% 44
2021
Q2 		$3.16M Buy
45,840
+285
+0.6% +$19K 0.72% 42
2021
Q1 		$2.94M Sell
45,555
-444
-1% -$28.6K 0.71% 44
2020
Q4 		$2.68M Buy
45,999
+31,516
+218% +$1.9M 0.7% 41
2020
Q3 		$915K Sell
14,483
-50
-0.3% -$3.47K 0.27% 68
2020
Q2 		$1.12M Buy
14,533
+3
+0% +$230 0.34% 61
2020
Q1 		$1.09M Sell
14,530
-500
-3% -$34.5K 0.41% 59
2019
Q4 		$977K Sell
15,030
-2,850
-16% -$186K 0.29% 67
2019
Q3 		$1.13M Sell
17,880
-2,250
-11% -$147K 0.34% 64
2019
Q2 		$1.36M Sell
20,130
-1,060
-5% -$69.7K 0.41% 60
2019
Q1 		$1.38M Hold
21,190
– – 0.39% 61
2018
Q4 		$1.32M Sell
21,190
-7,170
-25% -$501K 0.45% 53
2018
Q3 		$2.19M Buy
28,360
+880
+3% +$66.5K 0.65% 45
2018
Q2 		$1.95M Buy
27,480
+5,530
+25% +$391K 0.68% 41
2018
Q1 		$1.66M Buy
21,950
+1,635
+8% +$130K 0.54% 47
2017
Q4 		$1.46M Buy
20,315
+745
+4% +$56.6K 0.45% 53
2017
Q3 		$1.59M Buy
19,570
+4,845
+33% +$370K 0.51% 50
2017
Q2 		$1.04M Buy
14,725
+2,850
+24% +$190K 0.34% 61
2017
Q1 		$807K Buy
11,875
+7,275
+158% +$512K 0.29% 63
2016
Q4 		$329K Sell
4,600
-12,615
-73% -$938K 0.11% 98
2016
Q3 		$1.36M Buy
17,215
+4,350
+34% +$353K 0.5% 53
2016
Q2 		$1.07M Buy
12,865
+4,100
+47% +$364K 0.41% 59
2016
Q1 		$805K Buy
8,765
+1,350
+18% +$122K 0.34% 65
2015
Q4 		$750K Buy
7,415
+3,665
+98% +$381K 0.32% 70
2015
Q3 		$368K Buy
+3,750
New +$416K 0.16% 85
2015
Q1 		– Sell
-50
Closed -$5K – 365
2014
Q4 		$5K Hold
50
– – ﹤0.01% 318
2014
Q3 		$5K Buy
+50
New +$4.9K ﹤0.01% 323

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

American Research & Management Company's GILD Position: Q3 2022 in Review

American Research & Management Company reduced its Gilead Sciences (GILD) stake by 4.5% in Q3 2022, selling an estimated $106K and leaving 35,315 shares worth $2.18M. The position accounts for 0.6% of the portfolio, ranked #50.

American Research & Management Company first reported a position in GILD in Q3 2014 and has held it in 31 quarters since. The position peaked at $3.16M in Q2 2021. 1,603 funds tracked by Wall St. Rank hold GILD as of Q3 2022.

  • American Research & Management Company held 35,315 shares of Gilead Sciences worth $2.18M as of Q3 2022.
  • American Research & Management Company sold 1,677 Gilead Sciences shares in Q3 2022, an estimated $106K.
  • Gilead Sciences made up 0.6% of American Research & Management Company's portfolio in Q3 2022, its #50 holding.
  • American Research & Management Company first reported a position in Gilead Sciences in Q3 2014 and has held it in 31 quarters since.
  • American Research & Management Company's Gilead Sciences position peaked at $3.16M in Q2 2021.
  • 1,603 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2022.

Based on American Research & Management Company's 13F filing for Q3 2022, filed 7 Oct 2022.